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Background: Metastasis via the lymphatic system is promoted by lymphangiogenesis. Alterations of the lymphatic
channels during the progression of metastasis to regional lymph nodes (LNs) remain unexplored. To examine
whether tumor-induced LN lymphangiogenesis controls metastasis to regional LNs, we investigated cervical LN
metastasis in a mouse model of oral melanoma.
Methods: Injection of B16F10 melanoma cells into mouse tongues replicated spontaneous cervical LN metastasis.
We performed histological, immunofluorescent, and histomorphometric analyses of tumor-reactive
lymphadenopathy and lymphangiogenesis in tumor-associated LNs. We investigated the expression of vascular
endothelial growth factor (VEGF)-C and its receptor, VEGF receptor-3 (VEGFR-3), in tumor cells and tissues, and LNs
by reverse transcription polymerase chain reaction and immunofluorescence.
Results: Tumor-associated LNs comprised sentinel LNs (SLNs) before and after tumor cell invasion (tumor-bearing
SLNs), and LNs adjacent or contralateral to tumor-bearing SLNs. Extensive lymphangiogenesis appeared in SLNs
before evidence of metastasis. After metastasis was established in SLNs, both LNs adjacent and contralateral to
tumor-bearing SLNs demonstrated lymphangiogenesis. Interaction between VEGF-C-positive melanoma cells and
VEGFR-3-positive lymphatic vessels was evident in tumor-associated LNs.
Conclusions: LN lymphangiogenesis contributes a progression of tumor metastasis from SLNs to other regional
LNs.
Keywords: Sentinel lymph node, Tumor-bearing lymph node, Oral melanoma, Lymphangioegnesis, Lymphatic
metastasisBackground
The lymphatic system functions in regulating tissue fluid
balance and immune cell trafficking, and it is involved in
the pathogenesis of edema and metastasis. Tumor cell
dissemination to lymph nodes (LNs) through the lymph-
atic system is common and early event in human malig-
nant tumors. LN metastasis is the first sign of tumor
progression in most malignant tumors, and is a crucial
determinant in their staging, prognosis, and treatment
[1]. Lymphatic metastasis was considered a passive
process, where detached tumor cells entered LNs via
pre-existing lymphatic vessels proximate to the primary
tumors [2]. Sentinel LNs (SLNs) are defined as the first* Correspondence: johno@college.fdcnet.ac.jp
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reproduction in any medium, provided the orLNs to receive cells and fluid from primary tumors
through lymphatic vessels [3]. Malignant cells at SLNs
were believed to then enter the blood stream via high
endothelial venules or continue through the lymphatic
drainage system, exiting into the blood stream via anas-
tomoses such as the thoracic duct [4].
Changes in LNs begin before metastasis, a process
termed tumor-reactive lymphadenopathy [5]. Regional
LNs proximate to the primary tumors are commonly
enlarged because of reactive lymphadenopathy, tumor
metastasis, or both, suggesting that LN alteration
results from interactions between tumors and the
lymphatic system. Experimental tumor models and
human clinicopathological data indicate that lymphatic
vessel growth near solid tumors is often associated
with LN metastasis [6,7]. In melanoma, the level of
tumor-related lymphangiogenesis correlates with thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demonstrated that tumor cells in several malignancies
can induce lymphangiogenesis in SLNs before metas-
tasis [6,9-12]. Although it is known that structural
changes to SLNs are required for premetastatic condi-
tions, changes to regional LNs remain unexplored.
Lymphangiogenic factors promoting formation of tumor
lymphatics and metastasis of tumor cells to LNs have been
identified [13,14]. These factors include the secreted glyco-
proteins vascular endothelial growth factor (VEGF)-C and
VEGF-D, which activate VEGF receptor-3 (VEGFR-3), a cell
surface receptor tyrosine kinase expressed on lymphatic
endothelium [15,16]. VEGF-C or VEGF-D overexpression
is known to promote tumor lymphangiogenesis and tumor
dissemination in animal models [17-19], whereas inhibition
of VEGFR-3 signaling blocks these phenomena [20]. Simi-
larly, in human cancers, increased VEGF-C or VEGF-D ex-
pression is related to metastasis and poor prognosis [13,14],
whereas VEGF-A and VEGF-C-induced lymphangiogenesis
in LNs contributes to metastasis [10,12]. These observa-
tions support that VEGF-C or VEGF-D and VEGFR-3 sig-
naling pathway is required for tumor lymphangiogenesis
induction. However, much remains undiscovered about
contribution of this pathway to lymphangiogenesis in the
regional LNs proximal to tumors.
Appropriate animal models are necessary to study
detailed changes to regional LNs during lymphatic metasta-
sis. To characterize LN metastasis, we established a mouse
model of spontaneous LN metastasis according to Iwahashi
et al. in which injection of B16 melanoma cells into mouse
tongues is known to replicate spontaneous cervical LN me-
tastasis [21]. Although regional LNs must be affected by
primary tumors and metastatic SLNs, conclusive evidence
for this phenomenon does not exist. We focused on tumor-
related lymphangiogenesis in LNs proximate to oral melan-
oma in mice. Our study had three goals:
1. To histologically characterize regional LNs proximal
to tumors.
2. To investigate increased lymphangiogenesis in LNs by
histomorphometric analysis of lymphatic vessel endothelial
hyaluronan receptor 1 (LYVE-1) -positive areas.
3. To examine an interaction of VEGF-C with VEGFR-3
in LN lymphangiogenesis using dual
immunofluorescence.
Our results indicate that tumor-associated LNs show ex-




The mouse melanoma cell line, B16/F10 (RCB2630), was
provided by the RIKEN BRC through the NationalBioResource Center through the National Bio-Resource
Project of the Ministry of Education, Culture, Sports and
Technology (Ibaraki, Japan). Cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM; Invitro-
gen, Carlsbad, CA, USA) supplemented with 10% fetal
calf serum and penicillin/streptomycin. Cells were cul-
tured in vitro until confluent and were detached with
0.25% trypsin/0.02% ethylenediaminetetraacetic acid
(EDTA) solution. These cells were then used for the
metastatic model, cell immunostaining, and total RNA
extraction.
Animals and the spontaneous LN metastasis model
Female C57BL/6 mice (6–8 weeks old) were purchased
from Kyudo Co., Ltd. (Saga, Japan). All animal studies were
conducted using protocols approved by the Animal Care
and Use Committee, Fukuoka Dental College. For the spon-
taneous LN metastasis model, tumor cells (1 x 105 in 50 μl
DMEM) were injected submucosally into the left border of
the tongue [21]. Control mice were untreated.
To trace lymphatic drainage, 10 μl Evan’s blue dye (0.4%)
in phosphate-buffered saline (PBS) was injected into sites of
melanoma cell inoculation 15 min before sacrifice.
Tissue preparation
Cervical LNs were excised 1–21 days after injection from
three animals in each treatment group. On the terminal
day, the weight of each LN was measured, and the
specimens immediately frozen in liquid nitrogen. Frozen
specimens were cut into sections of 6-μm thickness and
stained with hematoxylin and eosin (HE) to visualize
histopathological changes. Frozen sections were also used
for immunofluorescence and extraction of total RNA.
Immunofluorescence
Tissue sections and B16F10 cells were fixed with 4%
paraformaldehyde in PBS for 15 min at 4°C, then washed
in PBS. To evaluate lymphangiogenesis in tumor-
associated LNs, we simultaneously performed three
types of double immunofluorescent staining on frozen
sections comprising two mixtures of two primary anti-
bodies, goat anti-mouse/rat tyrosinase-related protein 1
(TRP-1, 1:100; Santa Cruz Biotechnology, Inc., Sata
Cruz, CA, USA) and biotinylated anti-mouse LYVE-1
(1:200; R&D Systems, Minneapolis, MN, USA) and rat
anti-mouse CD45RB (1:100; Acris Antibodies, Herford,
Germany) and biotinylated anti-mouse LYVE-1 and a
mixture of rat anti-mouse CD31 (1:100; Becton Dickin-
son and Co., Franklin Lakes, NJ, USA) and biotinylated
anti-mouse LYVE-1 for 2 h at room temperature. After
washing with PBS, sections were incubated in a mixture
of anti-goat immunoglobulin G (IgG) antibody conju-
gated with Alexa Fluor 488 or anti-rat IgG antibody con-
jugated with Alexa Flour 488 (1:200; Molecular Probes,
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Alexa Fluor 568 (1:400; Molecular Probes) for 30 min at
room temperature. These two simultaneously incubated
double immunofluorescence stainings were applied to
examine the codistribution of VEGF-C and Fms-related
tyrosine kinase 4 (Flt-4, or VEGFR-3) in tumor-
associated LNs. A mixture of anti-rabbit IgG conjugated
with Alexa Flour 488 (1:200; Molecular Probes) and
anti-rat IgG conjugated with Alexa Flour 568 (1:200;
Molecular Probe) was overlaid on tissue sections for 45
min at room temperature, followed by preincubation
with mixture of rabbit anti-mouse VEGF-C (1:00; Angio-
Proteomie, Boston, MA, USA) and rat anti-mouse
VEGFR-3 (Flt-4, 1:100; BioLegend, San Diego, CA, USA)
for 2 h. For immunofluorescent staining of B16F10 cells,
paraformaldehyde-fixed cells were incubated with
VEGF-C antibody (1:200; Angio-Proteomie) for 1 h and
were then visualized with anti-rabbit IgG conjugated
with Alexa Flour 488 (1:200; Molecular Probes) for 30
min at room temperature. Immunostained sections and
cells were then counterstained with 4, 6-diamidino- 2-
phenylindole (DAPI; Vector Laboratories, Inc., Burlin-
game, CA, USA).
Lymphatic vessel area
Lymphatic vessel area was measured in 616 x 484-mm
LYVE-1-stained LN section images at 100x magnifica-
tion using ImageJ (National Institutes of Health,
Bethesda, MD, USA). Statistical analysis was performed
with the two-tailed Student’s t-test. Data were presented
as the mean ±standard error and P values of < 0.05 were
considered statistically significant.
RT-PCR
Total RNA was isolated from B16F10 cells and
serial frozen sections of tumor-bearing LNs by acidFigure 1 Gross findings of tongue and sentinel lymph node on day 5
Blackish swelling (arrow) in the left side of tongue. (B) Cut surface of tongu
sentinel lymph node (arrow).guanidiniumthiocyanate-phenol-chloroform extraction
using an ISOGEN kit (Nippon Gene Co., Ltd., Tokyo,
Japan). Isolates were quantified, and their purity evalu-
ated spectrophotometrically. Reverse transcription PCR
(RT-PCR) was performed using the Access RT-PCR Sys-
tem (Promega Corp., Fitchburg, WI, USA) according to
the manufacturer’s instructions. We used the following
primers: human VEGF-C, 5’-TTACAGACGGCCATG
TACGA-3’ (forward) and 5’-TTTGTTAGCATGGACC
CACA-3’ (reverse: product size 288 bp), and human
glyceraldehyde-3-phosphate dehydrogenase (G3PDH),
5’-TCCACCACCCTGTTGCTGTA-3’ (forward) and 5’-
ACCACAGTCCATGCCAT-3’ (reverse: product size 450
bp). Amplification was performed by a thermal cycler
for 35 cycles as follows: 30s of denaturation at 94°C, 30 s
of annealing at 60°C, and 1 min of extension at 72°C for
all primers. Amplified products were resolved on 1.2%
agarose/Tris-acetate EDTA gels (NacalaiTesque, Inc.,
Kyoto, Japan) electrophoresed at 100 mV, and then
visualized with ethidium bromide.
Results
Tumor-associated LN enlargement
B16F10 melanoma cells reliably underwent metastasis to
the tumor-draining cervical LNs following their injection
into the tongues of syngeneic C57BL/6 mice (Figure 1)
[21]. Tumor-associated LNs were divided into three
groups by their location:
a. SLNs
b. tumor-bearing SLNs
c. LNs adjacent or contralateral to tumor-bearing SLNs.
SLN
First, we examined SLNs before metastasis by assessing
histopathological changes and deposition of Evan’s bluein the spontaneous lymph node metastasis model of mice. (A)
e showing a relatively circumscribed, blackish tumor. (C) Metastasis in
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deposition of Evan’s blue dye was evident in superficial
cervical LNs located at the poles of the left subman-
dibular glands (Figure 2A). In contrast, contralateral
LNs were normal-sized, despite also being stained by
the dye. We designated the enlarged left cervical LNs
with as the SLNs draining the oral melanoma
(Figure 2B). Weight increased fivefold in this SLN rela-
tive to untreated controls (Figure 2C). SLN enlarge-
ment began 1 day after melanoma cell inoculation.
These results implied that before metastasis, SLNs
show tumor-reactive lymphadenopathy. Histologically,
enlarged SLNs showed remarkable medullary hyperpla-
sia (Figure 2D). The hyperplastic medulla consisted of
an increased number of lymphatic sinuses of increased
dilatation (Figure 2E) that contained few lymphocytes
and macrophages.Figure 2 Non-metastatic cervical sentinel lymph nodes in oral melano
showing remarkable enlargement, by injection of Evan’s blue dye. In contra
enlargement. (B) Photograph of an enlarged SLN (arrow) on the left side o
significantly increased in nonmetastatic SLNs relative to control, non-draini
standard error. (D), (E) Light micrographs of hematoxylin and eosin staining
medulla (Me) is noted. Dilated sinuses (MeS) are clearly visible in the Me of
Cortex; LyN, lymphatic nodule; MeC, medullary cord. Scale bars = 50 μm.Tumor-bearing SLNs
Next, we examined pathological changes in tumor-
bearing SLNs. In this model, LN metastases were
detected 2 days after inoculation (Figure 3A). By 12 days,
rates of metastasis exceeded 90%. Most mice died before
21 days because of eating disorder caused by enlarged
tumor of the tongue [21]. Tumor metastasis was
indicated macroscopically by the deposition of melanin
in SLNs, in addition to LN enlargement (Figure 3B).
After 10 days, some tumor-bearing mice possessed
bilateral metastases in cervical LNs (Figure 3C). To
elucidate the patterns of invasive patterns of tumor cell
invasion into SLNs [22], we analyzed HE-stained
sections of nodes (Figure 3D). On day 2 and day 3,
most LNs revealed a Grade 1 pattern of invasion, tumor
cells were detected from the subcapsular sinus to
the follicles. After day 5, tumor-bearing LNs showedma-bearing mice. (A) Detection of a sentinel lymph node (SLN),
st, contralateral LN (CLN) is also stained with dye, but shows no
f the cervix and a normal-like CLN (arrowhead). (C) LN weight is
ng LNs as determined by t-test. *, P<0.05. Columns, mean; bar,
in SLNs. At a lower magnification (D), remarkable enlargement of the
SLNs (E). ALV, afferent lymphatic vessels; SS, subcapsularsinuse; Co,
Figure 3 Tumor-bearing cervical lymph nodes in oral melanoma-bearing mice. (A) The lymph node (LN) metastasis rates of this model at
different time points. (B), (C) Photographs showing enlargement and deposition of melanin in cervical LNs 4 (B) and 10 (C) days after injection of
B16/F10 melanoma cells into the left side of tongue. After 10 days, tumor-involvement with LNs on both sides is increased (C). (D) Histological
grading of melanoma cell invasion in LNs, on hematoxylin and eosin-stained sections, as follows: Grade 1, proliferation of melanoma cells is
confined from the marginal sinus to the follicles; Grade 2, invasion of melanoma cells extends within the LN parenchyma; Grade 3, tumor cells
occupy >60% of the LN area. Scale bar = 5 μm. (E) Change in LN weight of tumor-bearing sentinel LNs. Weights of tumor-bearing LNs increased
significantly, compared with hat controls. Columns, mean; bar, standard error. *, P<0.05 relative to controls.
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the paracortex in Grade 2 invasion. In Grade 3 invasion,
>60% of LN-areas were occupied by tumors. In addition
to tumor-invasion, these LNs showed expansion of the
lymphatic medulla. A 2.8-, 4.4-, and 4.2-fold increase
was observed in Grade 1, 2, and 3 LNs, respectively,
when compared with untreated controls (Figure 3E).
Changes in tumor-bearing SLNs were similar to those
attributed to tumor-reactive lymphadenopathy in SLNs
before metastasis.
LNs proximal to tumor-bearing SLNs
After establishment of metastasis in SLNs, adjacent and
contralateral LNs also demonstrated enlargement
(Figures 4A and B). Compared with untreated controls,
2.2- and 3.9-fold increases were evident in adjacent and
contralateral LNs, respectively (Figure 4C). Histological
changes in adjacent and contralateral LNs were similar
to those in nonmetastatic and tumor-bearing SLNs,
increased number of lymphatic sinuses of increased dila-
tation (Figures 4D and E). Changes in adjacent andcontralateral LNs after SLN metastasis resembled those
of tumor-reactive lymphadenopathy.
Lymphangiogenesis occurs in cervical LNs showing
tumor-reactive lymphadenopathy
Cervical LNs showing tumor-reactive lymphadenopathy
were examined to determine whether vessels in these
lymphatic organs change with tumor growth. We used
the anti-mouse LYVE1 antibody to identify the lymph-
atic endothelium [23,24]. Control LNs double-stained
with CD45RB and LYVE-1 antibodies showed sparse
lymphatic sinuses expressing LYVE-1, restricted to the
subcapsular margins (data not shown). However, non-
metastatic SLNs showed numerous enlarged lymphatic
sinuses throughout the cortex and medulla (Figures 5A
and B). Particularly, linear fluorescence of LYVE-1 was
evident in the border of dilated lymphatic sinuses in the
medullary portion (Figure 5B). These findings indicate
that tumors somehow promote expansion of lymphatic
sinuses in proximate LNs. We quantified the area occupied
by LYVE-1-positive lymphatic channels in nonmetastatic
Figure 4 Lymph nodes adjacent and contralateral to tumor-bearing sentinel lymph nodes in oral melanoma-bearing mice. (A) Lymph
nodes (LNs) (arrow) adjacent to tumor-bearing sentinel LNs (SLNs) (arrowhead) showing enlargement. (B) Enlarged LNs (arrow) contralateral to
tumor-bearing SLNs (arrowhead). (C) Changes in weight of LNs adjacent and contralateral to tumor-bearing SLNs. Columns, mean; bar, standard
error. *, P<0.05 relative to the control. (D) Photograph of adjacent LN (arrow) showing medullary hyperplasia to tumor-bearing SLN (t-SLN;
arrowhead). Scale bar = 50 μm. (E) Photograph of LNs contralateral to tumor-bearing SLN. Both LNs show medullary hyperplasia. Scale bar = 50 μm.
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images [22]. The mean measured values demonstrated a
33.8-fold increase in non-metastatic SLNs relative to con-
trol LNs (Figure 5C).
Tumor-bearing LNs double-stained with TRP-1 and
LYVE-1 antibodies, showed invasion of TRP-1-positive
melanoma cells into LNs and an increase in LYVE-1-
positive sinuses in the medulla, regardless of invasive
grade (Figures 6A-C). In comparison with nonmetastatic
SLNs, collapsed lymphatic sinuses from the hilum to the
medulla were frequently observed (Figure 6D). The
mean measured values of LYVE-1-positive areas revealed
a 13.3-, 29.1-, and 28.6-fold increase in Grade 1, 2, and 3
LNs, respectively, when compared with untreated con-
trols (Figure 6E).
Finally we examined whether tumor-bearing SLNs
could induce lymphangiogenesis in adjacent and contra-
lateral LNs. In LNs adjacent and contralateral to nonme-
tastatic SLNs showing increased LYVE-1-positive sinuses,
the intensity and distribution of LYVE-1-positive sinuseswere similar to those in untreated control LNs (data not
shown). Conversely, LNs adjacent and contralateral to
tumor-bearing SLNs showed a remarkable increase in
LYVE-1-positive sinuses (Figures 7A and B). Measurement
of LYVE-1-positive areas demonstrated a 33.8- and
23.7-fold increase in adjacent and contralateral LNs,
respectively, relative to control LNs (Figure 7C). LNs
adjacent and contralateral to tumor-bearing SLNs showed
lymphangiogenesis in a pattern similar to that obtained in
SLNs before and after tumor invasion, suggestive of pre-
metastatic conditions.
Immunohistochemical interactions between VEGF-C and
VEGFR-3 in tumor-associated LNs
Recent studies demonstrated that VEGF-C/VEGFR-3
signaling promotes tumor lymphangiogenesis and con-
tributes to the promotion of metastasis [13,14]. We
examined immunohistochemical interactions between
VEGF-C and its receptor, Flt-4 (VEGFR-3), in tumor-
associated LNs. First, we demonstrated VEGF-C mRNA
Figure 5 Lymphangiogenesis in nonmetastatic sentinel lymph nodes. (A), (B) Double immunofluorescent images of CD45RB (green) and
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1; red) in nonmetastatic sentinel lymph nodes (SLN). Increase in LYVE-1-positive
lymphatic sinuses is evident in both subcapsular margins (A) and medulla (B). sm, subcapsular margins; Me, medulla; f, follicle; pc, paracortex.
Scale bar = 50 μm. (C) Measurement of LYVE-1-positive lymphatic sinus area in control LNs and nonmetastatic SLNs. A significant increase was
observed in non-metastatic SLNs, compared with untreated controls. Columns, mean; bar, standard error. *, P<0.001 relative to controls.
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LN tissues by RT-PCR (Figure 8A). VEGF-C mRNA ex-
pression was evident in both cells and tissues. Immuno-
fluorescent detection of VEGF-C revealed a cytoplasmicFigure 6 Increase in lymphatic vessel endothelial hyaluronan recepto
(A)-(D) Double immunofluorescent images of tyrosinase-related protein 1 (
(LYVE-1; red) in tumor-bearing lymph nodes (LNs). Tumor-bearing sentinel
LYVE-1-positive sinus area in the medulla. High-magnification images of the
melanoma cells. (E) Measurement of LYVE-1-positive lymphatic sinus area in
bar, standard error. *, P<0.05 relative to controls. **, P<0.001 relative to conlocation in B16F10 cells (Figure 8B). Next, we performed
double immunofluorescent staining for VEGF-C and Flt-
4 in primary melanoma of the tongue (Figure 8C),
tumor-bearing SLNs (Figure 8D), and LNs adjacent tor 1 positive sinus areas in tumor-bearing sentinel lymph nodes.
TRP-1; green) and lymphatic vessel endothelial hyaluronan receptor 1
LNs in Grade 1 (A), Grade 2 (B), and Grade 3 (C) showed increases in
medullary portion of Grade 3 LN (D). Arrowheads, TRP-1-positive
control LNs and tumor-bearing LNs of each grade. Columns, mean;
trols.
Figure 7 Lymphangiogenesis in lymph nodes adjacent and contralateral to tumor-bearing sentinel lymph nodes. (A), (B) Double
immunofluorescent images of tyrosinase-related protein 1 (TRP-1; green) and lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1; red) in
lymph nodes (LNs) adjacent (A) and contralateral (B) to tumor-bearing sentinel LNs (SLNs), showing an increase in LYVE-1-positive sinuses in the
medulla. aLN, adjacent lymph node; cLN, contralateral lymph node; arrowhead, TRP-1-positive melanoma cells. Scale bar = 50 μm. (C)
Measurement of LYVE-1-positive lymphatic sinus area in LNs adjacent and contralateral to tumor-bearing SLNs. Columns, mean; bar, standard
error. *, P<0.001 relative to controls.
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nomas and tumor-bearing SLNs, close interaction was
observed between VEGF-C-positive melanoma cells and
Flt-4-positive lymphatic vessels. Adjacent LNs showed
increased Flt-4-positive sinuses from the hilum to the
medulla. Tumor-associated LNs without metastasis such
as SLNs and LNs contralateral to metastatic SLNs also
showed increased sinuses expressing Flt-4 (data not
shown). In control LNs, anti-Flt-4 antibody was unreact-
ive with lymphatic sinuses (data not shown).Discussion
Despite increasing evidence supporting involvement of
the lymphatic system in the metastasis of various malig-
nant tumors, little is known about the mechanism of
continuous spreading of tumors via regional LNs. In this
study, we established an experimental model of cervical
LN metastasis to investigate changes in tumor-
associated LNs such as SLNs before metastasis, tumor-
bearing SLNs, and LNs adjacent or contralateral to
tumor-bearing SLNs. We present three lines of evidence
to support the conclusion that lymphangiogenesis is
evident in tumor-associated regional LNs. First, all
tumor-associated LNs exhibited tumor-reactive lymph-
adenopathy. Second, measurement of the LYVE-1-positive
areas in tumor-associated LNs indicated extensive
lymphangiogenesis. Third, immunohistochemical inter-
action of VEGF-C with VEGFR-3 was examined in LN
lymphangiogenesis.Both macroscopic and microscopic observations indi-
cate that LNs proximate to oral melanoma show tumor-
reactive lymphadenopathy regardless of the presence of
tumor cells. The dilated lymphatic sinuses evident in
tumor-associated LNs differ from those evident in in-
flammatory lymphadenopathy, which are full of lympho-
cytes [9]. These differences suggest that alternate
mechanisms underlie sinus expansion in tumor-
associated LNs. Previous studies demonstrated that ex-
pansion of lymphatic sinuses is induced in tumor-
draining LNs before metastasis [9,11]. Our observations
in SLNs without metastasis support this hypothesis.
Sinus expansion in tumor-bearing LNs was also reported
by Harrell et al. [11]. Interestingly, we found that tumor-
bearing SLNs could induce changes in both adjacent and
contralateral LNs. Both adjacent and contralateral LNs,
similarly to SLNs with or without metastases, showed
enlargement and sinus expansion. These observations
led us to speculate that changes in both adjacent and
contralateral LNs constitute premetastatic condition for
tumor dissemination via the lymphatic vessels from
metastatic SLNs.
Immunohistochemical quantification of the LYVE-1-
positive area revealed lymphangiogenesis in all tumor-
associated LNs. These results indicate that extensive
lymphangiogenesis is significantly correlated with tumor-
reactive lymphadenopathy in these LNs. In this study,
tumor-induced lymphangiogenesis was evident in tumor-
draining SLNs before tumor cell invasion. This supports
recent observations that SLN lymphangiogenesis precedes
Figure 8 Correlation between Vascular endothelial growth factor C and Fms-related tyrosine kinase expressions in tumor-associated
lymph nodes. (A) Expression of Vascular endothelial growth factor C (VEGF-C) mRNA detected by reverse transcription PCR in B16/F10 cells and
tumor-bearing lymph nodes (LNs). Glyceraldehyde-3-phosphate dehydrogenase expression was used as a loading control. (B)
Immunofluorescence image of VEGF-C expression in B16/F10 cells. Scale bar = 50 μm. (C)-(E) Double immunofluorescence images using
antibodies specific for VEGF-C (green) and Fms-related tyrosine kinase (Flt-4; red) in primary melanoma of the tongue (C), tumor-bearing sentinel
LNs (D), and LNs adjacent (aLN) to tumor-bearing LNs (E). Photographs show an increase in Flt-4-positive lymphatic vessels and sinuses. Scale
bars = 50 μm.
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mainly in the medullary region, following tumor cell inva-
sion into SLNs. After metastasis was established in SLNs,
lymphangiogenesis expanded to LNs adjacent or contra-
lateral to metastatic SLNs. These results suggest that
tumors in SLNs act over a distance to induce lymphangio-
genesis within regional LNs.
In this study, we considered tumor-reactive lymph-
adenopathy to result from extensive lymphangiogenesis,
suggesting that tumor-derived signals are transported via
the lymphatic system to tumor-associated LNs where
they induce lymphangiogenesis. Recent studies reported
that VEGF-C activates lymphatic vessel growth by
stimulating VEGFR-3 expressed on lymphatic endothe-
lium [12,14]. RT-PCR and immunohistochemical ana-
lyses in our study demonstrated expression of VEGF-C
mRNA and VEGF-C protein in cultured B16F10 cells
and melanoma-bearing tissues. These results suggest
that tumor cells are actively responsible for lymphangio-
genesis by producing of VEGF-C. Double immunofluor-
escent staining showed that VEGF-C in tumor cellspromotes increased expression of its receptor, Flt-4, on
lymphatic endothelia. In both primary tongue tumors
and tumor-bearing SLNs, lymphatic vessels close to
tumor cells expressed Flt-4. Interestingly, an increase in
Flt-4-positive LN sinuses was observed in all tumor-
associated LNs. A recent study proposed that VEGF-C-
induced lymphangiogenesis in SLNs promotes tumor
metastasis to distant sites [12]. In our study, even
though only immunohistohcemical results, LN lymphan-
giogenesisis seems to be partly mediated by VEGF-C/
VEGFR-3 signaling and to promote in tumor metastasis
from SLNs to adjacent and/or remote LNs. Future work
using the knocked-down expression of VEGF-C in
tumor cells will address the detailed mechanisms of LN
lymphangiogenesis mediated by VEGF-C/VEGFR-3 sig-
naling in this model.
Conclusions
In conclusions, our findings demonstrate that all tumor-
associated LNs exhibit tumor-reactive lymphadenopathy,
histologically characterized by extensive lymphangiogenesis.
Ozasa et al. Journal of Experimental & Clinical Cancer Research 2012, 31:83 Page 10 of 10
http://www.jeccr.com/content/31/1/83These data suggest that LN lymphangiogenesis is premeta-
static condition in regional LNs and contributes to metasta-
sis from SLN to remote LNs.
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